www射-国产免费一级-欧美福利-亚洲成人福利-成人一区在线观看-亚州成人

Global EditionASIA 中文雙語(yǔ)Fran?ais
Business
Home / Business / Companies

Boehringer Ingelheim confident of its China prospects

By Lin Shujuan | chinadaily.com.cn | Updated: 2023-03-30 18:44
Share
Share - WeChat
Dr. Pavol Dobrocky, president and CEO of Boehringer Ingelheim China. [Photo provided to chinadaily.com.cn]

Boehringer Ingelheim remains confident about its future business development in China, which it considers to be one of its most important markets and a source of innovation, company executives said during a media briefing in Shanghai on Thursday.

The German pharmaceutical company saw a 10.5 percent increase in its global sales despite a slight fall in China revenue, which fell 8.9 percent from the previous year, according to its 2022 annual report which was released on Wednesday.

BI said the drop in revenue in China was largely due to the COVID-19 pandemic.

"We are confident in future growth and believe we will see better numbers in 2023 because of the removal of all the restrictions," said Dr. Pavol Dobrocky, president and CEO of BI China.

Dobrocky said the company is committed to a long-term presence in China and will focus on three key aspects – innovation, digitalization and sustainable development – to drive the company's future growth in the country.

In the next five years, BI will invest more than 90 million euros ($97.85 million) in China to expand its production bases and upgrade existing technology, said Dobrocky.

"China is seen as a focus market because it offers a huge opportunity for our innovation to benefit many patients as there are many unmet medical needs, as well as opportunities in innovation and digitalization," he added.

Despite the impact that COVID-19 had on the market last year, BI nevertheless managed to achieve several major breakthroughs in China. In December 2022, the company's innovative rare skin disease medication, Spevigo, was approved by China's National Medical Products Administration, making it the first innovative drug developed by a multinational pharmaceutical company to be registered and approved almost simultaneously in China and around the world.

In 2022, the company also delivered a series of unique digital solutions in China, including Consanas Cloud, a digital platform that provides physical and occupational therapies as part of home-based rehabilitation training for stroke patients with mild and moderate symptoms.

BI China also saw its human pharma production and supply site in Zhangjiang, Shanghai become the first carbon neutral pharmaceutical plant certified by both Guangzhou Emission Exchange and TUV Rheinland last year.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 亚洲 欧美 激情 另类 自拍 | 青青自拍 | 视频一区二区在线 | 国产精选在线视频 | 国产精品亚洲一区二区在线观看 | 18黄网站 | 日韩精品一区二区三区在线观看l | 精品欧美一区二区三区在线观看 | 国产孕妇做受视频在线观看 | 久草在线在线观看 | 怡红院老首页主页入口 | 日本免费www| 国产精品99r8在线观看 | 久久一本精品久久精品66 | 国产精品日韩欧美一区二区三区 | 国产成人丝袜网站在线观看 | 日韩欧美精品一区二区 | 高清在线亚洲精品国产二区 | 欧美一区二区精品 | 亚洲日本高清成人aⅴ片 | 中国精品视频一区二区三区 | 黄色网址免费在线 | 国产永久免费视频m3u8 | 欧美日韩亚洲国产精品 | 国产成人免费视频精品一区二区 | 欧美国产精品 | 在线看片亚洲 | 高颜值美女啪啪 | 国产特级全黄一级毛片不卡 | 97精品国产91久久久久久 | 欧美精品v欧洲精品 | 国产亚洲精品一区二区三区 | 亚洲视频 欧美视频 | 国产成人综合亚洲亚洲欧美 | 国产综合亚洲专区在线 | 国内精品久久久久影院老司 | 天天插夜夜爽 | 国产2区 | 久久国产精品久久国产片 | 在线免费观看一级片 | 性8sex亚洲区入口 |